What is Stryker Mako?

Stryker Mako: large-footprint orthopedic market-leader archetype

Stryker Mako is a large-footprint CT-based robotic-arm-assisted orthopedic surgical system from Stryker (NYSE: SYK). Per DEPLOY's surgical cluster framework, Mako anchors the large-footprint orthopedic market-leader archetype within the surgical cluster's Wave 3 orthopedic sub-cohort triangle alongside Smith+Nephew CORI (handheld) and Zimmer Biomet ROSA (mid-size cross-domain).

Stryker: NYSE: SYK; HQ Portage, MI (CORRECTED from Kalamazoo)

Stryker is a publicly-traded medical-technology company (NYSE: SYK) headquartered in Portage, Michigan. Per Agent A orthopedic ingest, the HQ location is Portage, MI (NOT Kalamazoo as aggregator coverage often frames). The Portage corporate-HQ correction is editorially significant at the entity-verification layer per cap-flag-as-trust-signal: primary-source-anchored HQ verification operates as the load-bearing entity-identification framing. The framework-in-action correction is documented at canonical worked-example depth in Stryker isn't headquartered in Kalamazoo.

$1.65B MAKO Surgical acquisition 2013

Stryker acquired MAKO Surgical for $1.65B in 2013, integrating the Mako platform into Stryker's orthopedic + surgical product portfolio. Per DEPLOY's framework, the 2013 acquisition timing matters editorially: Stryker's Mako consolidation predates the broader new-defense + cross-domain surgical-robotics scaling era; Mako's market-leader positioning within orthopedic-robotic surgery is rooted in the post-2013 Stryker integration.

FDA-cleared multi-procedure scope (broader than aggregator framing)

Per Agent A orthopedic ingest, Mako is FDA-cleared across multi-procedure scope broader than aggregator coverage often frames:

• Partial knee: cleared (foundational Mako indication).
• Total knee: cleared.
• Cementless knee: cleared.
• Hip: cleared.
• Hip-revision: cleared.
• Spine: cleared via K241517.
• Shoulder: cleared via K242373.

Per DEPLOY's framework, the multi-procedure clearance scope is editorially significant at the cohort-architecture layer: trade-press coverage that frames Mako narrowly as "knee + hip robotic surgery" operates outside Agent A primary-source-anchored verification of the broader spine + shoulder clearance scope. Per cap-flag-as-trust-signal, the K241517 + K242373 spine + shoulder clearances are the load-bearing primary-source verification anchors for the expanded multi-procedure scope.

CT-based pre-op planning + robotic-arm-assisted intra-op

Per Agent A orthopedic ingest, Mako operates a two-stage workflow structurally distinct from imageless-orthopedic-robotic alternatives:

• CT-based pre-op planning: pre-operative CT imaging informs patient-specific implant + cut plan; computational planning drives intra-op execution targets.
• Robotic-arm-assisted intra-op: large-footprint robotic arm assists surgeon during procedure with planned-cut bounds + tracking.

Per DEPLOY's framework, the CT-based + large-footprint architecture is editorially distinct from Smith+Nephew CORI's handheld imageless approach + Zimmer Biomet ROSA's mid-size architecture. The orthopedic sub-cohort form-factor variance is a load-bearing structural axis.

AI-augmented surgeon-controlled assistance (NOT autonomous)

Per Agent A orthopedic ingest + DEPLOY's surgical cluster framework, Mako operates AI-augmented surgeon-controlled assistance, NOT autonomous-robotic surgery: software plans + tracks + bounds; the surgeon makes the cuts. Per DEPLOY's framework, this is the same assistive class as Intuitive da Vinci + Moon Surgical Maestro: augmentation rather than replacement of surgeon decision-making.

The AI-augmented-surgeon-controlled framing matters editorially across the cohort: trade-press coverage that frames orthopedic-robotic systems as "autonomous surgical robots" operates outside Agent A primary-source-anchored verification. Per cap-flag-as-trust-signal, the assistive-vs-autonomous distinction is the load-bearing verification posture; the surgical-cohort framework applies the AI-augmented-not-autonomous framing consistently across all orthopedic-robotic anchors (Stryker Mako + Smith+Nephew CORI + Zimmer Biomet ROSA).

Market-share framing: SEC discipline (cap-flag aggregator share figures)

Per Agent A orthopedic ingest, Stryker's SEC framing positions itself as "one of four leading global competitors" with NO specific market-share percentage asserted. Per cap-flag-as-trust-signal, the SEC framing is the load-bearing primary-source verification anchor; aggregator-quoted specific market-share figures are cap-flagged pending primary-source confirmation. Per DEPLOY's framework, trade-press coverage citing specific Mako market-share percentages without SEC-disclosed primary-source confirmation operates outside verification posture.

Cohort positioning: large-footprint orthopedic market-leader archetype

Per the surgical cluster framework, Stryker Mako anchors:

• Large-footprint orthopedic market-leader archetype: CT-based pre-op planning + robotic-arm-assisted intra-op; multi-procedure platform scope.
• Wave 3 orthopedic sub-cohort triangle: Mako (large-footprint) + Smith+Nephew CORI (handheld) + Zimmer Biomet ROSA (mid-size cross-domain); parallels biometric ring sub-cohort triangle pattern within surgical form_factor.
• SEC-disclosed parent-company verification depth: NYSE: SYK; Portage, MI HQ; "one of four leading global competitors" framing.
• AI-augmented-surgeon-controlled-not-autonomous: consistent framing across orthopedic sub-cohort.

Contrast with cohort:

• Smith+Nephew CORI: handheld imageless orthopedic; knee-only robotic scope (hip is navigation-only, NOT robotic).
• Zimmer Biomet ROSA: mid-size multi-procedure platform spanning orthopedics + neurosurgery (knee + hip + brain + shoulder).
• Intuitive da Vinci: replacement-robotics soft-tissue market-leader; 11,395 da Vinci + 1,041 Ion systems installed.
• Moon Surgical Maestro: assistive-laparoscopy commercial-niche; FDA 510(k) K240598 (Jun 2024).
• CMR Versius: international commercial soft-tissue; UK-headquartered modular architecture.

Consumer pricing surface for Stryker Mako is forthcoming via Agent B's planned orthopedic sub-cohort /price triangle; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's ship. Registry institutional depth at Stryker registry company + Mako registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the handheld orthopedic sub-cohort contrast, see what is Smith+Nephew CORI. For the mid-size cross-domain contrast, see what is Zimmer Biomet ROSA. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Stryker Mako: the 4-way autonomy-boundary taxonomy (AI-augmented operator-controlled tier; surgeon makes cuts, software bounds) + verified-vs-claimed at within-entity granularity (CANONICAL multi-procedure within-entity clearance state: knee + hip + spine K241517 + shoulder K242373) + the 9-tier source-quality rubric (FDA + Stryker SEC source classification).